

Hester Biosciences Limited

Formerly Hester Pharmaceuticals Limited

Regd. Office : Village : Merda-Adraj, Ta : Kadi , Dist : Mehsana, Gujarat - 382 721

Audited Financial Results for the year ended on 31st March, 2008

Rs.In Lacs

Sr.No.	Particulars	Nine Months ended on	Quarter ended on	Previous Quarter ended on	Year ended on	Previous year ended
		31/12/2007	31/03/2008	31/03/2007	31/03/2008	31/03/2007
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Manufacturing Sales	2586.42	637.62	591.13	3224.04	2160.11
	Trading Sales	31.19	8.13	5.81	39.32	22.68
	Net Income from Sales	2617.61	645.75	596.94	3263.36	2182.79
2	Other Income	27.09	0.41	18.87	27.50	26.32
3	Total Income	2644.70	646.16	615.81	3290.86	2209.11
4	Total Expenses	1486.97	447.48	375.22	1934.45	1345.73
	(a) (Increase)/decrease in Stock in trade	-71.77	-127.19	-196.32	-198.96	-225.42
	(b) Trading Purchase	38.74	3.58	3.66	42.32	30.46
	(c) Consumption of Raw material	439.43	188.74	327.89	628.17	709.37
	(d) Manufacturing Expenses	266.01	75.15	66.98	341.16	222.10
	(e) Staff Cost	212.63	86.77	57.47	299.40	196.40
	(f) Depreciation	270.16	98.30	15.92	368.46	44.09
	(f) Selling, General & Admn.Expenses	331.77	122.13	99.62	453.90	368.73
5	Interest	204.39	61.10	30.50	265.49	69.77
6	Profit Before Tax	953.34	137.58	210.09	1090.92	793.61
7	Provision for taxation	320.00	66.86	76.43	386.86	278.48
8	Net Profit	633.34	70.72	133.66	704.06	515.13
9	Paid-up equity share capital	519.12	519.12	519.12	519.12	519.12
10	Reserves & Surplus				2849.86	2275.58
11	EPS (Rs.) (not annualised)	12.20	1.36	2.44	13.56	11.14
12	Aggregate of Non Promoters					
	- Number of Share	2952124	2952124	2969424	2952124	2969424
	- % of Shareholding	56.87	56.87	57.20	56.87	57.20

Notes :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 24.6.2008
- The Board has recommended a Dividend of Rs. 2.50 per share of Rs. 10 each (25 %), subject to the approval of shareholders at the ensuing Annual General Meeting
- Segment wise reporting as per accounting Standard (AS-17) is not applicable, since the entire operation of the Company relates to only one segment i.e. "Poultry Vaccines"
- Provision for taxation includes deferred Tax of Rs. 21.60 lacs and Fringe Benefit Tax of Rs. 5.25 lacs for the current year, as per AS-22.
- No Investor were pending at the beginning of the quarter. During the quarter two complaints were received and resolved. Pending complaint at the end of the quarter was nil
- Earning per Share has been calculated on the basis of paid up share capital
- The figures have been re-grouped / rearranged wherever necessary.

By Order of the Board

Place : Ahmedabad
Date : 24th June, 2008

Rajiv Gandhi
CEO & Managing Director